Evidence map›Paper›PMID 33549625›Full record

ArticleThe Journal of infection2021

Early clinical experience with imatinib in COVID-19: Searching for a dual effect.

Alejandro Morales-Ortega, Luis Rivas-Prado, Begoña Frutos-Pérez, Beatriz Jaenes-Barrios, Ana Isabel Farfán-Sedano, Carlos Javier García-Parra, Belén Hernández-Muniesa, Miguel Ángel Duarte-Millán, Elena Madroñal-Cerezo, Ana Ontañón-Nasarre and 6 more

Open access · bronzeAbstract readLetterComment
In one paragraph

Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Alejandro Morales-OrtegaDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: alejandro.morales@salud.madrid.org.
Luis Rivas-PradoDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Begoña Frutos-PérezDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Beatriz Jaenes-BarriosPrimary Health Care Center Castilla La Nueva, Fuenlabrada, Madrid, Spain.
Ana Isabel Farfán-SedanoDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Carlos Javier García-ParraDepartment of Emergency Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Belén Hernández-MuniesaDepartment of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Miguel Ángel Duarte-MillánDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Elena Madroñal-CerezoDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Ana Ontañón-NasarreDepartment of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.
José Manuel Ruiz-GiardínDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Fernando BermejoDepartment of Gastroenterology, Hospital Universitario de Fuenlabrada. Instituto de Investigación, Sanitaria Hospital La Paz (IdiPAZ), Madrid, Spain.
Mario García-GilDepartment of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Sonia Gonzalo-PascuaDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Juan Víctor San Martín-LópezDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
David Bernal-BelloDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Hospital Universitario de Fuenlabrada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19AmidesHumansImatinib MesylatePyrazinesSARS-CoV-2Treatment OutcomeAmidesfavipiravirImatinib MesylatePyrazines

Identifiers

PMID33549625
PMCPMC7862035
OpenAlexW3127403971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.